Valuation : Intellia Therapeutics, Inc.

Market Cap 1.79B 1.54B 1.45B 1.32B 2.47B 169B 2.48B 17.08B 6.63B 86.48B 6.7B 6.56B 279B P/E 2026 *
-3.99x
P/E 2027 * -4.82x
Enterprise Value 1.45B 1.25B 1.17B 1.07B 2B 137B 2.01B 13.84B 5.37B 70.1B 5.43B 5.32B 226B EV / Sales 2026 *
27.9x
EV / Sales 2027 * 11.2x
Free-Float
96.16%
Yield 2026 *
-
Yield 2027 * -
1 day+0.47%
1 week-1.01%
Current month+0.08%
1 month+13.35%
3 months-5.91%
6 months-5.21%
Current year+41.71%
1 week 12.28
Extreme 12.28
13.13
1 month 11.41
Extreme 11.41
13.73
Current year 9.05
Extreme 9.05
18.48
1 year 7.95
Extreme 7.95
28.25
3 years 5.9
Extreme 5.9
38.71
5 years 5.9
Extreme 5.9
168.35
10 years 5.9
Extreme 5.9
202.73
Manager TitleAgeSince
Chief Executive Officer 68 2017-12-31
Director of Finance/CFO 51 2024-07-21
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 68 2014-06-30
Chairman 63 2020-01-31
Director/Board Member 74 2018-10-30
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 Sell

Chief Executive Officer

-2,785 0.0020%
7/22/26 Sell

Chief Financial Officer

-8,111 0.0058%
7/2/26 Sell

Chief Financial Officer

-4,677 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.47%-1.01%+5.64%-66.64% 1.79B
-0.90%-2.64%-1.54%+14.01% 48.93B
-0.40%+1.03%+418.57%+527.30% 45.01B
-1.42%+2.30%+42.67%+22.37% 44.07B
-1.22%-2.31%+4.82%+77.49% 40.73B
+0.53%-1.36%+16.87%+46.82% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+120.75% 16.5B
-1.29%-1.02%+12.33%+31.50% 14.67B
-1.65%-1.03%+75.93%+41.12% 13.77B
Average -0.64%+0.38%+66.30%+90.52% 27.68B
Weighted average by Cap. -0.75%+0.10%+88.80%+127.55%

Financials

2026 *2027 *
Net sales 51.88M 44.64M 42M 38.37M 71.78M 4.9B 71.97M 496M 193M 2.51B 195M 191M 8.1B 125M 108M 102M 92.8M 174M 11.85B 174M 1.2B 466M 6.08B 471M 461M 19.58B
Net income -420M -361M -340M -311M -581M -39.66B -583M -4.02B -1.56B -20.35B -1.58B -1.54B -65.55B -374M -322M -303M -277M -518M -35.35B -519M -3.58B -1.39B -18.14B -1.41B -1.38B -58.43B
Net Debt -338M -291M -274M -250M -468M -31.93B -469M -3.23B -1.26B -16.38B -1.27B -1.24B -52.77B -376M -324M -305M -278M -521M -35.53B -522M -3.6B -1.4B -18.23B -1.41B -1.38B -58.73B
Logo Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
Employees
377
Date Price Change Volume
26-09-04 US$12.74 +0.47% 2,796,288
26-09-03 US$12.68 -0.63% 3,004,964
26-09-02 US$12.76 +0.59% 3,245,595
26-09-01 US$12.69 -0.35% 2,184,155
26-08-31 US$12.73 -1.09% 2,925,419
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
12.74USD
Average target price
23.94USD
Spread / Average Target
+87.92%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTLA Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!